Celltrion Healthcare Wins UNDP Bid... "Supplying Truxima and Vegzelma to Turke"

Celltrion Healthcare announced on the 1st that it has succeeded in winning the bid for anticancer drug procurement held by the United Nations Development Programme (UNDP) and will supply 'Truxima (active ingredient Rituximab)' and 'Vegzelma (active ingredient Bevacizumab)'.

Begzelma. [Photo by Celltrion Healthcare]

UNDP is a subsidiary organization of the United Nations (UN) that promotes economic and social development in developing countries by providing special fund formation, technical assistance, and pharmaceutical support.

Celltrion Healthcare received the anticancer drug bidding plan from UNDP in May and participated, recently achieving final success in the bid. According to the results of this bid, it plans to supply Truxima and Vegzelma to Turkmenistan, a Central Asian country, targeting the end of this year.

Celltrion Healthcare emphasized the significance of fulfilling the inherent role of a biopharmaceutical company by contributing to the improvement of medical welfare for patients in developing countries through this UNDP bid win. At the same time, it stressed that meaningful achievements in the international organization's bidding competition will further increase product preference in medical fields.

As of the second quarter, Truxima recorded a market share of 33% in the UK (IQVIA), 32% in Belgium, and 22% across Europe. In the United States, it showed a stable prescription rate with a market share of 30% (Symphony Health) as of the third quarter this year. Additionally, Vegzelma has been increasing prescriptions since its launch in Europe last October, recording market shares of 45% in Finland and 21% in Germany.

A Celltrion Healthcare official stated, "We find it meaningful to provide Celltrion Group’s pharmaceuticals to patients suffering from diseases who are also struggling to secure treatments through this UNDP bid win. We are confident that Truxima and Vegzelma, as high-quality biopharmaceuticals with proven therapeutic efficacy, will establish themselves not only in advanced markets with systematic medical systems such as the US and Europe but also as optimal treatments for patients in developing countries. We plan to further expand our participation in supply through international organizations going forward."

This content was produced with the assistance of AI translation services.